Physicians at 500 cancer treatment centers in the U.S. have been certified to prescribe Novocure’s (NASDAQ:NVCR) Optune’ to newly diagnosed and recurrent glioblastoma (GBM) patients.
Optune is Novocure’s wearable, portable, FDA-approved Tumor Treating Fields (TTFields) delivery system. Physicians at an additional 291 medical institutions throughout the world also can prescribe Optune to GBM patients.
In Novocure’s phase 3 pivotal EF-14 clinical trial, newly diagnosed GBM patients treated with Optune together with temozolomide demonstrated a significant increase in progression free and overall survival compared to patients treated with temozolomide alone. EF-14 patients treated with Optune together with temozolomide experienced a 70 percent improvement in survival rate at four years compared to patients treated with temozolomide alone.
‘By certifying more physicians throughout the U.S. and globally, we are making Optune more accessible for GBM patients who could benefit from treatment with TTFields,’ said Peter Melnyk, Novocure’s Chief Commercial Officer. ‘We are proud to have met this milestone, and are committed to raising awareness of the therapy and making it readily available to the patients who need it.’
About Novocure
Novocure is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed phase 2 pilot trials investigating TTFields in non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.
